RESEARCH ARTICLE

Identification of druggable small molecule antagonists of the *Plasmodium falciparum* hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering

Monique R. Heitmeier1☯, Richard C. Hresko1☯, Rachel L. Edwards1, Michael J. Prinsen2, Ma Xenia G. Ilagan2, Audrey R. Odom John1,3, Paul W. Hruz1,4*

1 Department of Pediatrics, Washington University School of Medicine, St Louis, MO, United States of America, 2 High Throughput Screening Center, Washington University School of Medicine, St Louis, MO, United States of America, 3 Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, United States of America, 4 Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO, United States of America

☯ These authors contributed equally to this work.

* hruz_p@wustl.edu

Abstract

Although the *Plasmodium falciparum* hexose transporter PfHT has emerged as a promising target for anti-malarial therapy, previously identified small-molecule inhibitors have lacked promising drug-like structural features necessary for development as clinical therapeutics. Taking advantage of emerging insight into structure/function relationships in homologous facilitative hexose transporters and our novel high throughput screening platform, we investigated the ability of compounds satisfying Lipinski rules for drug likeness to directly interact and inhibit PfHT. The Maybridge HitFinder chemical library was interrogated by searching for compounds that reduce intracellular glucose by >40% at 10 μM. Testing of initial hits via measurement of 2-deoxyglucose (2-DG) uptake in PfHT over-expressing cell lines identified 6 structurally unique glucose transport inhibitors. WU-1 (3-(2,6-dichlorophenyl)-5-methyl-N-[2-(4-methylbenzenesulfonyl)ethyl]-1,2-oxazole-4-carboxamide) blocked 2-DG uptake (IC₅₀ = 5.8 ± 0.6 μM) with minimal effect on the human orthologue class I (GLUTs 1–4), class II (GLUT8) and class III (GLUT5) facilitative glucose transporters. WU-1 showed comparable potency in blocking 2-DG uptake in freed parasites and inhibiting parasite growth, with an IC₅₀ of 5.8 ± 0.6 μM and EC₅₀ of 5.5 ± 0.6 μM, respectively. WU-1 also directly competed for N-[2-

---

OPEN ACCESS

Citation: Heitmeier MR, Hresko RC, Edwards RL, Prinsen MJ, Ilagan MXG, Odom John AR, et al. (2019) Identification of druggable small molecule antagonists of the *Plasmodium falciparum* hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering. *PLoS ONE* 14(5): e0216457. https://doi.org/10.1371/journal.pone.0216457

Editor: Stuart Alexander Ralph, University of Melbourne, AUSTRALIA

Received: March 4, 2019
Accepted: April 23, 2019
Published: May 9, 2019

Copyright: © 2019 Heitmeier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This research was supported by grants from the National Institutes of Health (AI130584, AI103280, AI123808) and the Burrows Welcome Fund (1015493). The funders had no role in study
modification resulted in a concomitant increase in affinity for 4,6-O-ethylidene-α-D-glucose, an exofacially directed transport antagonist, but did not alter the $K_m$ for 2-DG. Taken together, these data are consistent with a model in which WU-1 binds preferentially to the transporter in an inward open conformation and support the feasibility of developing potent and selective PfHT antagonists as a novel class of anti-malarial drugs.

Introduction

Despite intensive efforts to control the spread of infection with Plasmodium species, the causative agent of malaria, disease prevalence remains alarmingly high, with over 219 million new cases world-wide in 2017 alone [1]. While substantial investment of monetary and intellectual resources to combat malaria has resulted in a 93% decline in mortality over the past 5 years, over 435,000 deaths still occur annually, mostly in children [1]. The emergence of parasite resistance to all available therapeutics including delayed clearance to artemisinin-based compounds has hindered efforts to eradicate this devastating disease [2]. Thus, there is an ongoing need to develop novel anti-malarial agents with high potency, low production cost, sustained efficacy within disease endemic areas, and favorable pharmacokinetic profiles that allow single dose treatment regimens [3]. With recent advances in understanding the molecular mechanisms responsible for parasite replication, new avenues have emerged for the design and implementation of effective mitigation strategies [4, 5].

One highly promising approach is to directly interfere with parasite hexose transport. Glucose is the primary source of energy needed by blood-stage parasites for biomass production and ATP synthesis. The malarial glucose transporter, Plasmodium falciparum hexose transporter (PfHT), first identified by Woodrow et al. in 1999 [6] is essential for parasite survival [7]. Chemical validation of PfHT as an antimalarial target was accomplished with the discovery of compound 3361, a glucose analog, as an antagonist of Plasmodium hexose transporter [8, 9]. Compound 3361 is highly selective for PfHT over the human orthologue GLUT1 and also inhibits asexual intra-erythrocytic growth in culture [8]. Compound 3361 is also active against P. berghei liver and transmission stage parasites, suggesting that PfHT may have highly desirable full life cycle activity [8, 10]. However, while 3361 validates efforts to target PfHT, this compound is not itself considered drug-like and is therefore not a viable candidate for lead development [9].

GLUT1 activity is also important for glucose uptake into red blood cells and hepatocytes and GLUT1-mediated uptake has been shown to be enhanced in Plasmodium berghei-infected cells [11]. Inhibition of GLUT1 under these circumstances may be beneficial for inhibiting P. berghei infection. However, due to the ubiquitous expression of this transporter and its critical role in maintaining basal glucose delivery to tissues, inhibition of GLUT1 would be expected to result in significant host toxicity.

Initial efforts to screen for additional small molecule PfHT antagonists was performed in hexose transport null mutants of Leishmania mexicana parasites engineered to heterologously express the Plasmodium falciparum transporter [12]. This approach yielded several bioactive compounds with varying potency and selectivity for PfHT over the mammalian transporter GLUT1. The physical and pharmacokinetic profile of these pre-lead hits are not sufficient for use as an orally bioavailable drug and will require extensive structure-activity analysis for optimization [12].
Our identification of the clinically marketed drug lopinavir, an HIV protease inhibitor, as a direct antagonist of PfHT further advanced this pharmacological approach to block parasite replication. However, lopinavir has a relatively poor potency (16 μM IC₅₀) against blood stage parasites and shows higher selectivity for the human insulin-responsive glucose transporter GLUT4 over PfHT [13]. Drugs that block GLUT4 activity induce insulin resistance [14]. Therefore, the development of novel therapeutics targeting PfHT requires identification of compounds with substantially improved potency and selectivity over the human GLUT orthologues.

To facilitate the identification of novel chemical scaffolds with potent inhibitory activity toward PfHT, we developed a robust high-throughput screening assay that allows real-time detection of intracellular glucose levels in cell lines engineered to selectively over-express a single facilitative glucose transporter. This assay has been validated by screening of the MMV Malaria Box of 400 compounds with known anti-malarial activity [15]. Similar to compound 3361, the novel hits from this screen do not possess sufficient drug-like structure for pharmaceutical development. We therefore sought to begin with a chemical library specifically designed to follow Lipinski’s rules for potential as an orally deliverable drug. The Maybridge HiFinder collection, consisting of 14,399 small molecules with drug-like diversity and chemical stability, provided a suitable screening platform. We report here the identification of several novel chemical scaffolds for hit-to-lead optimization and characterization of both potency and selectivity for PfHT over human glucose transporters.

With the further goal of developing drugs that will maintain efficacy during widespread clinical use, we have characterized the physical interaction of inhibitory compounds with the transporter. Given that hexose transport is essential for parasite survival, we hypothesized that compounds that bind to PfHT within the glucose permeation pathway will be less susceptible to resistance, since mutations that reduce drug affinity would be more likely to also impair transporter function. We here provide evidence for structural interactions between WU-1 and PfHT protein in light of the current rocker-switch model for transporter conformational dynamics [16]. As discussed in detail in this report, these data can facilitate the development of novel antimalarial drugs that are less susceptible to parasite resistance through mutational change. This information also provides novel insight on the conformational dynamics of the family of structurally related facilitative hexose transporters.

**Materials and methods**

**Materials**

WU-1 (3-(2,6-dichlorophenyl)-5-methyl-N-[2-(4-methylbenzenesulfonyl)ethyl]-1,2-oxazole-4-carboxamide, cat# 002-890-346), WU-2 (3-(3-bromo-2,6-dimethoxy-5-nitrobenzoyl)-1-(2-chloro-6-methylphenyl)urea, cat# 002-892-269), WU-3 (2-(amino-5-phenyl-N’-[(E)-(3,4,5-trimethoxyphenyl)methylidene]thiophene-3-carboxhydrazide, cat# 002-903-252) and WU-5 ((3E,5E)-3,5-bis[(3,4,5-trimethoxyphenyl)methylidene]oxan-4-one, cat# 001-840-877) were purchased from MolPort, Riga, Latvia. [¹⁴C]2-deoxyglucose ([¹⁴C]2-DG), [³H]2-DG (2-DG), [³H]D-fructose (D-Frc), [³H]-D-glucose, and [³H]-L-glucose were purchased from American Radiolabels Inc. (St. Louis, MO). GLUT1 short hairpin RNA (shRNA) was obtained through the RNA interference (RNAi) core at Washington University School of Medicine. HEK293 cells were acquired from the American Type Culture Collection (ATCC). Egg phosphatidylcholine (eggPC), palmitoyloleoyl phosphatidylethanolamine (POPE), and palmitoyloleoyl phosphatidic acid (POPA) were purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Lauryl maltose neopentyl glycol (LMNG) detergent was obtained from Anatrace (Maumee, OH). PEG-biotin cap-ATB-BMPA was purchased from Toronto
Research Chemicals, Inc. (Ontario, Canada). FLAG tag rabbit antibody (2368) was obtained from Cell Signaling Technology (Danvers, MA). All other reagents were purchased from Sigma or as otherwise indicated.

**PfHT antibodies**

Rabbit antisera raised against a synthetic PfHT carboxy-terminal peptide (amino acids 481–496 (C-GGEIGTSPYITMEEIRQ)) were prepared by ABclonal Technology (Woburn, MA) and used in the immunoblot analyses.

**Cell line generation**

Generation of HEK293 cells overexpressing PfHT and human GLUTs 1–4 were described elsewhere [13, 15]. Briefly, HEK293 cells were transfected with pcDNA3.1 FLII12Pglu-7006 (Addgene), containing the fluorescence resonance energy transfer (FRET) glucose sensor (HEK293-FLIP) and PfHT, human GLUT1 (hGLUT1), hGLUT2, hGLUT3, hGLUT4, hGLUT5 or hGLUT8 using OptiFect (Life Technologies) according to manufacturer’s specifications. To increase retention of GLUT8 at the plasma membrane, the dileucine sorting signal E7E8XXXLL was modified to R7R8XXXLL as described in [17]. Stable transfectants were selected for G418 and hygromycin resistance to select for FRET sensor and hexose transporter, respectively. HEK293-FLIP cells were also used to generate cells stably transfected with FLAG-tagged PfHT (FTPfHT). FLAG tag (DYKDDDDK) followed by a triple glycine linker and a tobacco etch virus (TEV) protease site (ENLYFQS) followed by a triple glycine linker was added to the N-terminus of PfHT via PCR [18] using Phusion Hot Start II High-Fidelity DNA Polymerase (Fisher Scientific). Single clones were selected by comparing their abilities to transport glucose as assayed via FRET and radiolabeled hexose uptake. In all cell lines, except for HEK293 cells overexpressing hGLUT1 and hGLUT5, native hGLUT1 was knocked down using shRNA as described elsewhere [13]. Transcript levels of the individual GLUTs expressed in each cell line are as described in [13, 15] and in S1 Fig.

**High-throughput screening**

Black opaque 384-well plates (Greiner Bio-One) were pretreated with 25 μg/ml of polyethylenimine (PEI; 750 kDa; Sigma-Aldrich) solution containing 150 mM NaCl to maintain cell adhesion during washing steps. After 20 min of incubation at room temperature, PEI was aspirated and wells were air dried for 5 min. Using a Multidrop384 dispenser (Thermo Fisher Scientific), PfHT-FLIP cells were plated at 20,000 cells/well. After cell plating, plates were left in the sterile hood at room temperature for 45 min before transfer to the incubator which helped reduce edge effects [19]. Compound screening was performed the following day using the integrated and automated screening system (Beckman Coulter) at the Washington University High Throughput Screening Center. SAMI EX software (Beckman Coulter) was used to design and execute the screening protocol. Maybridge HitFinder library compounds were pre-dispersed into 384-well Greiner polypropylene plates (Cat# 781280) using the Hummingbird XL. Using a Multidrop Combi dispenser, the compounds were prediluted in glucose-free HEPES-buffered saline solution (HBSS) (146 mM NaCl, 4.7 mM KCl, 0.6 mM MgSO₄, 1.6 mM NaHCO₃, 0.13 mM NaH₂PO₄, 2.5 mM CaCl₂, 20 mM HEPES [pH 7.3]). We prepared a 1:900 dilution of 10 mM stock solution of the compounds for an 11.11 μM final concentration. DMSO (0.11% DMSO) and cytochalasin B (CB, 200 μM) were used as negative and positive controls for inhibition, respectively. To initiate the screening assay, cells were washed twice with 50 μl of HBSS per well using an ELx405 plate washer (Biotek), then incubated for 30 minutes (starvation period) after addition of 45 μl of diluted compound using the BiomekFX...
Liquid Handler (Beckman Coulter). To initiate the uptake, 5 μl of 50 mM glucose was added to the wells (final compound concentration, 10 μM; final glucose concentration, 5 mM) using a Multidrop384 dispenser (Thermo Fisher Scientific). After incubation at room temperature for 120 min, fluorescence was measured using a 2102 EnVision multilabel plate reader (PerkinElmer) at an excitation wavelength of 436 nm (cyan fluorescent protein [CFP]) and emission wavelengths of 485 nm (CFP) and 535 nm (yellow fluorescent protein [YFP]). % inhibition was determined using the plate controls by subtracting the YFP/CFP ratio (FRET ratio) for CB controls from that of the vehicle (DMSO) controls and then calculating the % decrease in signal for each single point compound tested.

**P. falciparum culture**

*P. falciparum* strain 3D7 was obtained from the Malaria Research and Reference Reagent Resource Center (MR4, ATCC, Manassas, VA). Parasites were cultured in a 2% suspension of human erythrocytes and RPMI 1640 (Sigma) medium supplemented with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 μg/ml gentamicin, and 0.5% Albumax (Gibco) at 37˚C, 5% O₂/ 5% CO₂ / 90% N₂ atmosphere as previously described [20, 21].

**P. falciparum growth inhibition assays**

Asynchronous *P. falciparum* cultures were diluted to 1% parasitemia and were treated with compounds at concentrations ranging from 0.195 μM—100 μM. Growth inhibition assays were performed in 100 μl cultures in opaque 96-well plates. Parasite growth was quantified after 3 days by measuring DNA content using Picogreen (Life Technologies)[22]. Fluorescence was measured by a FLUOstar Omega microplate reader (BMG Labtech) at 485 nm excitation and 528 nm emission. IC₅₀ values were calculated by least squares nonlinear regression analysis using GraphPad Prism 6.0 software.

**P. falciparum hexose uptake**

Glucose uptake by *P. falciparum* was performed essentially as described [23]. *P. falciparum* strain 3D7 was cultured in 100 mm tissue culture dishes (Techno Plastic Products) in a 2% suspension of human erythrocytes and RPMI 1640 medium until reaching > 7.5% parasitemia. Cells were pelleted via centrifugation and resuspended in RPMI 1640 medium. To determine the uptake of radiolabeled glucose into the parasite, parasites were isolated from infected erythrocytes by permeabilization with saponin (0.05 w/v), followed by centrifugation, aspiration of supernatant and washing of the pellet 3X with saline solution (135 mM NaCl, 2 mM KCl, 25 mM HEPES, 0.2 mM glucose and 1 mM MgCl₂; pH 7.1) to remove cellular debris. WU-1 or DMSO vehicle were added to 100 μl parasites (resuspended in saline) 5 min prior to the addition of 100 μl [¹⁴C]2-DG (0.2- μCi/ml final concentration). 2-DG uptake was stopped after 2 min by layering the entire reaction over 300 μl of an oil mixture (5:4 mix of dibutyl phthalate / dinonyl phthalate) in Eppendorf tubes and centrifuged at 15,850 × g for 2 mins. The ratio of the estimated intracellular concentration of radiolabel relative to the extracellular concentration were calculated as described [23]. Uptake of radiolabeled hexose into HEK293 cells was measured in glucose-free HBSS as described previously [24]. Briefly, cells were plated at 400,000 cells/well overnight at 37˚C in 24-well plates pre-treated with PEI. After 30-min incubation at 37˚C in glucose-free HBSS in the presence of vehicle or increasing concentrations of compound, 2-DG uptake was measured in glucose-free HBSS for 4 min at 37˚C. Cultures were washed in ice-cold 1X PBS and lysed in 0.1% Triton X-100 in 1X PBS. Radiolabeled hexose uptake was determined by liquid scintillation counting (Ultima Gold, Thermo Fisher) and
normalized to total protein per well. Uptake data are plotted as percent uptake relative to vehicle-treated cells. Kinetic analyses were performed using the indicated concentrations of substrate and WU-1, with quenching of uptake after 1 min incubation. Incubation times had been previously determined as being in the linear range of time-dependent radiolabeled hexose uptake (2 min for 2-DG uptake into freed parasites; 2 and 4 min for D-Frc and 2-DG uptake HEK cell lines, respectively). Data were fit by least squares nonlinear regression analysis using GraphPad Prism 6.0 software.

**Purification of FTPfHT**

SalI and NotI restriction sites were introduced to the 5’ and 3’ ends, respectively, of FTPfHT cDNA via PCR and then this construct was placed into the multiple cloning site of the pACMV-tetO vector [25]. Stable tetracycline-inducible HEK293S GnTI cell lines expressing FTPfHT were generated using the same protocol previously described for FTGLUT4 [26]. FTPfHT protein was solubilized from FTPfHT/HEK293S GnTI cell pellets with lauryl maltose neopentyl glycol (LMNG) detergent and purified using M2 anti-FLAG affinity gel (Sigma) as described in [27]. The FLAG tag was cleaved using tobacco etch virus (TEV) protease (plasmid purchased from Addgene, Cambridge, MA) at a ratio of 1:20 TEV/PfHT overnight at 4˚C in the presence of 1 mM DTT. Based on SDS-PAGE and Blue BANDit protein stain (Amresco, Solon, OH), PfHT protein after FLAG elution was ~95% pure.

**PfHT liposome reconstitution and [³H]-glucose uptake**

Liposomes containing PfHT were made according to Hresko et al. [27]. Briefly, purified PfHT protein in LMNG micelles described above were mixed with Triton X-100 destabilized eggPC/POPA/POPE (70:15:15) large unilamellar vesicles (lipid to protein ratio of 100–125:1 (w/w)). By slowly removing the detergents with Amberlite XAD-2 beads (Supelco Analytical, Bellefonte, PA), PfHT protein spontaneously inserts into the liposomes. After removal of the beads, liposomes were collected by ultracentrifugation, resuspended in buffer, and flash-frozen with liquid nitrogen. Frozen liposomes containing purified PfHT protein were thawed at room temperature followed by extrusion through a 200-nm polycarbonate filter to create liposomes of uniform size. Uptake was started by adding [³H]-D-glucose (1 μCi/ml, 200 μM cold D-glucose) to PfHT proteoliposomes at room temperature. Transport was stopped at different times with 5 ml of ice-cold quench buffer (50 mM potassium phosphate, 130 mM KCl, pH 7.4) and then filtered by vacuum on a 0.2-μm mixed cellulose ester filter (Advantec, Durham, NC). Filters were subsequently washed with an additional 10 ml of quench buffer. Scintillation fluid (Filter Count, PerkinElmer, Waltham, MA) was added to the filters and the radioactivity counted. [³H]-L-glucose (1 μCi/ml, 200 μM cold L-glucose) was used to determine nonspecific transport. Specific uptake was calculated by subtracting nonspecific [³H]-L-glucose from [³H]-D-glucose uptake. Uptake was normalized to the amount of transporter per reaction, determined by analyzing aliquots of transporter-containing liposomes along with a BSA standard curve on an SDS-polyacrylamide gel stained with Blue Bandit protein stain and quantified using an Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NB). Data were fitted by least squares nonlinear regression analysis using GraphPad Prism 6.0.

**Photolabeling of PfHT liposomes**

WU-1 inhibitor was added to PfHT liposomes for 10 min at room temperature. Samples (final volume, 110 μl) were then incubated for 10 min at room temperature with biotinylated ATB-BMPA (50 μM final concentration) and then placed on ice prior to UV irradiation. Reactions were transferred to a 24-well low protein retention culture dish (Costar, Corning, NY)
and then irradiated at room temperature 5 cm from a Green Spot UV lamp for 1 min (30 sec of light followed by 30 sec of darkness followed by 30 sec of light). Unbound ATB-BMPA was removed using a 0.5 ml Zeba Spin Column (Thermo Scientific, Rockford, IL). Samples were analyzed by immunoblot analysis using a fluorescently labeled streptavidin (LI-COR Biosciences, Lincoln, NE). The amount of PfHT protein in each sample was quantified by SDS-PAGE stained with Blue BANDIT protein stain using a BSA standard curve. The streptavidin signal was then normalized to the amount of PfHT protein.

Statistics
Statistical analysis between groups was performed using paired student’s t-test as indicated in Results and Figure Legends.

Results
Screening assay
Our aim was to identify potent and selective inhibitors of *P. falciparum* hexose transporter, PfHT. Using our novel FRET-based high-throughput HEK293PfHT screening assay [15], we screened the Maybridge HitFinder library of 14,399 compounds. This assay was optimized for high-throughput application in a 384-well format using the Z’ factor and the coefficient of variation (CV) as measures of assay robustness [28]. Dimethylsulfoxide (DMSO) and cytochalasin B (CB) were used as negative and positive controls for inhibition of glucose uptake (inhibition of FRET signal), respectively. We were able to routinely obtain a Z’ factor of ~0.8 (a perfect assay would have a Z’ factor of 1.0) and a CV of ~2%. Compounds were screened at a concentration of 10 μM for the ability to decrease the FRET ratio by more than 40%. We identified 407 compounds (2.8% hit rate) as potential hits for further analysis. Of these, 212 compounds were intrinsically fluorescent potential “false positives” and were removed from further consideration. The remaining 195 compounds were tested for glucose uptake inhibition via single point determination of inhibition of radiolabeled 2-deoxy-glucose (2-DG) uptake assay using PfHT-overexpressing HEK293 cells. 6 of the 195 potential hits, inhibited 2-DG uptake in PfHT-overexpressing HEK293 cells (> 40%) which translates to a confirmed hit rate of 0.042%.

Confirmation of hits using 2-DG uptake
Of the 6 confirmed hits, 4 compounds, "WU-1", "WU-2", "WU-3", and "WU-5", were commercially available and acquired for further characterization. We determined the potency of each compound to inhibit PfHT-mediated glucose uptake by 2-DG uptake IC₅₀ determinations. As shown in Fig 1, all four compounds inhibit PfHT with the order of inhibition WU-5 (1.9 μM) > WU-2 (4.2 μM) > WU-1 (5.8 μM) > WU-3 (9.2 μM).

Isoform selectivity determination, growth inhibition of *P. falciparum* 3D7, and inhibition of glucose uptake in freed parasites
To mitigate potential off-target effects of candidate PfHT antagonists on human glucose transporter orthologues, we used our novel HEK293 cell lines that were engineered to selectively over-express single GLUT isoforms. As shown in S1 Fig and references [13] and [15], quantitative PCR confirmed the desired expression of the single desired GLUT isoform over endogenous hexose transporters. We further determined that 2DG transport activity was at least 3-11-fold above the untransfected native HEK293 cell line (S2 Fig). This likely represents a lower limit of exogenous transporter contribution to glucose uptake, since it has previously been
shown that over-expression of exogenous GLUTs in this cell line results in suppression of endogenous transporter expression [29]. Using the IC_{50} concentration of each compound for the inhibition of PfHT, we determined the isoform selectivity of these compounds for PfHT vs. human GLUTs. As shown in Fig 2, compound WU-1 exhibited good selectivity for PfHT over the class I GLUTs, inhibiting only GLUT2 by ~10%. WU-2 was somewhat less selective, inhibiting GLUTs -2, -3 and -4 by ~10–12%. Compound WU-3 was non-selective, inhibiting
all the class I GLUTs by 50% or more at the PfHT IC$_{50}$ concentration. WU-5 did not inhibit GLUT1, but significantly inhibited GLUT2 (~70%), GLUT3 (~20%) and GLUT4 (~45%). Due to non-selectivity, characterization of compounds WU-3 and WU-5 was not pursued further and we continued with compounds WU-1 and WU-2.

To further characterize the specificity of WU-1 and WU-2 for PfHT over the human class I GLUT orthologues, we performed 2-DG uptake IC$_{50}$ determinations on GLUTs 1–4 (Fig 3). Both WU-1 and WU-2 exhibited similar potencies for PfHT at 5.8 ± 0.6 μM and 4.2 ± 0.8 μM, respectively (Table 1). Due to solubility issues, we were unable to test these compounds at concentrations higher than 225 μM. As a result, the IC$_{50}$ curves shown for WU-1 in Fig 3A are lacking data points that would comprise the lower asymptote of the curve that is necessary to accurately determine an IC$_{50}$. Thus while WU-1 is selective for PfHT vs. the class I GLUTs, WU-2 is less selective, inhibiting GLUTs 2 and -4, albeit with less efficacy than PfHT as demonstrated by the shallowness of the curves (Fig 3 and Table 1).

We next tested whether WU-1 and WU-2 inhibit asexual *P. falciparum* parasite growth in the *in vitro* *P. falciparum* growth inhibition assay [22]. As shown in Fig 4A, the EC$_{50}$ curves for WU-1 and WU-2 inhibition of parasite growth were 5.5 ± 0.6 μM and 22.8 ± 0.8 μM, respectively. Since the compounds need to traverse the erythrocyte membrane in order to reach the parasite, we hypothesize that the right-shift in IC$_{50}$ for WU-2 on the growth inhibition curve for *P. falciparum* is due to poor ADME (absorption, distribution, metabolism and excretion) characteristics for this compound. For this reason, as well as a diminished GLUT selectivity vs. WU-1, we focused on compound WU-1 for further characterization. The IC$_{50}$ for 2-DG uptake by isolated freed parasites for WU-1 (Fig 4B) was similar to the EC$_{50}$ growth inhibition curve for *P. falciparum* (6.1 ± 0.8 μM and 5.5 ± 0.6 μM, respectively). These data demonstrate

Fig 3. IC$_{50}$ determination of glucose uptake by HEK293 cells overexpressing human class I orthologues. 2-DG uptake in response to increasing WU-1 (A) or WU-2 (B) concentrations in HEK293 cells expressing the indicated GLUT protein. IC$_{50}$s were calculated using nonlinear regression analysis using GraphPad Prism 6.0 and are tabulated in Table 1. Uptake data are expressed as means ± SEMs of three independent experiments performed in triplicate.

https://doi.org/10.1371/journal.pone.0216457.g003

Table 1. IC$_{50}$ concentrations and maximal inhibition for WU-1 and WU-2 for class I GLUT overexpressing cells.

| Cell Line | WU-1 IC$_{50}$ (μM) | Maximum Inhibition (%) | WU-2 IC$_{50}$ (μM) | Maximum Inhibition (%) |
|-----------|---------------------|------------------------|---------------------|------------------------|
| PfHT      | 5.8 ± 0.6           | 93.2                   | 4.2 ± 0.8           | 84.4                   |
| GLUT1     | n.i.                | n.a.                   | n.i.                | n.a.                   |
| GLUT2     | >50                 | n.a.                   | 15.9 ± 2.5          | 62.0                   |
| GLUT3     | >100                | n.a.                   | >50                 | n.a.                   |
| GLUT4     | >100                | n.a.                   | 18.5 ± 3.5          | 40.0                   |

IC$_{50}$ determinations for 2-DG uptake by PfHT and GLUTs 1–4 were determined as described in Materials and Methods. n.i = Not inhibited; n.a. = not available.

https://doi.org/10.1371/journal.pone.0216457.t001
inhibition of PfHT in a cellular context and support an antiparasitic mechanism-of-action of WU-1 through inhibition of glucose uptake by PfHT. In addition to the class I GLUTs, we were also interested in determining whether WU-1 was selective for PfHT over the human class II and class III GLUTs. Using HEK293 cells overexpressing GLUT5 or GLUT8 as representatives of class II and class III GLUTs, respectively, we determined the WU-1 IC$_{50}$ for hexose uptake by these transporters. PfHT and GLUT8 transport both glucose and fructose while GLUT5 transports only fructose. The IC$_{50}$ for PfHT was similar for 2-DG and D-fructose uptake (5.8 ± 0.6 μM vs 5.0 ± 0.7 μM, Fig 5 and Table 2). WU-1 failed to inhibit fructose uptake by class II GLUT5 (Fig 5B) and exhibited selectivity for PfHT over GLUT8 for both 2-DG and D-fructose substrates (Fig 5 and Table 2). Taken together, these data suggest that WU-1 exhibits selectivity for PfHT over the human class I, II and III GLUTs.

Fig 4. Inhibition of growth and IC$_{50}$ determination of glucose uptake by isolated *P. falciparum* parasites. A) IC$_{50}$ for inhibition of growth of *P. falciparum* strain 3D7 intraerythrocytic forms by each compound were determined via a growth inhibition assay as described in Materials and Methods. Data are expressed as means ± SEMs of three independent experiments performed in duplicate. B) Uptake of 2-DG by isolated *P. falciparum* trophozoites at increasing concentrations of WU-1. Distribution ratios (i.e., the ratio of intracellular concentration of radiolabel relative to the extracellular concentration) were calculated as described previously [23, 50]. IC$_{50}$s were calculated using nonlinear regression analysis (GraphPad Prism 6.0). Uptake data are expressed as means ± SEMs of three independent experiments performed in triplicate. 

https://doi.org/10.1371/journal.pone.0216457.g004

Fig 5. IC$_{50}$ determination of hexose uptake by HEK293 cells overexpressing representative human class II and III orthologues. A) Uptake of 2-DG by HEK293 cells overexpressing either PfHT or class III GLUT transporter, hGLUT8. B) Uptake of [3H]-D-fructose (Frc) in HEK293 cells overexpressing hGLUT8, or PfHT or class II transporter, GLUT5. Uptake data are expressed as means ± SEMs of three independent experiments performed in triplicate. IC$_{50}$s were calculated using nonlinear regression analysis (GraphPad Prism 6.0) and are tabulated in Table 2. 

https://doi.org/10.1371/journal.pone.0216457.g005
WU-1 is a non-competitive inhibitor of PfHT-mediated fructose uptake

Kinetic analysis of hexose transport was performed to gain insight into the mode of action of WU-1 on PfHT. In order to obtain the clearest results, these experiments were carried out with fructose to eliminate any contribution from endogenous transporters. Fructose transport in these cell lines was over 20 fold above untransfected HEK293 cells (S2 Fig). PfHT is the only fructose transporter in PfHT-overexpressing HEK 293 cells. As shown in the Dixon Plot (Fig 6), the linear lines derived using different fructose concentrations intersect near the horizontal axis indicating that WU-1 is a non-competitive inhibitor of PfHT for zero-trans fructose uptake. The $K_i$ of 4.4 ± 0.3 μM, calculated from the horizontal intercepts, is consistent with the IC$_{50}$ for inhibition of fructose uptake in HEK293-PfHT cells (5.0 ± 0.7 μM, Table 2).

WU-1 directly inhibits both the binding of the glucose analogue (ATB-BMPA) and glucose uptake in PfHT liposomes

To verify that WU-1 inhibits PfHT-mediated glucose transport by directly interacting with PfHT, we engineered HEK293 cells stably overexpressing PfHT containing an N-terminal FLAG tag that can be cleaved using tobacco etch virus (TEV) protease. Using a protocol we developed to reconstitute GLUT4 into eggPC/POPA/POPE (70:15:15) liposomes [26, 27], we were able to purify FLAG-tagged PfHT to ~95% homogeneity using an M2 anti-FLAG affinity gel (Fig 7A). An immunoblot of PfHT liposomes using a FLAG-tag specific antibody revealed a major band ~38–40 kDa and two diffuse minor bands ~65–70 kDa (Fig 7B) all of which disappeared with cleavage of the FLAG tag via TEV protease. The same immunoblot bands appeared using a PfHT specific antibody that recognizes a peptide in the C-terminus (Fig 7B). TEV cleavage increased the mobility of both the major and minor bands. Our interpretation of

### Table 2. IC$_{50}$ concentrations and selectivity indices for WU-1 in GLUT5 and GLUT8 overexpressing cells.

| Cell Line | 2-DG (μM) | Selectivity Index | Frc (μM) | Selectivity Index |
|-----------|-----------|------------------|----------|------------------|
| PfHT1     | 5.8 ± 0.6 | 1.0              | 5.0 ± 0.7| 1.0              |
| GLUT5     | n.d.      | n.d.             | n.i.     | n.i.             |
| GLUT8     | 25.0 ± 7.5| 4.3              | 22.0 ± 1.2| 4.4              |

IC$_{50}$ determinations for 2-DG and [³H] D-fructose uptake by PfHT-, GLUT5- and GLUT8-over-expressing cells were determined as described in Materials and Methods. The selectivity indices for PfHT over the individual GLUT proteins was calculated using these numbers. n.d. = not determined; n.i. = Not inhibited.

https://doi.org/10.1371/journal.pone.0216457.t002

Fig 6. C-1 is a non-competitive inhibitor of PfHT. HEK293 cells were incubated with increasing concentrations of [³H]-D-fructose (Frc). Data were fit by non-linear regression analysis using GraphPad Prism 6.0 software. Uptake data are expressed as means ± SEMs (n = 3). Dixon plot shows WU-1 is a noncompetitive inhibitor with a $K_i$ of 4.4 ± 0.3 μM.

https://doi.org/10.1371/journal.pone.0216457.g006
the Western blot data is that the 38–40 kDa band represents full length PfHT and the 65–70 kDa band is likely a PfHT dimer that is commonly found in SDS gels of other glucose transporters (experimental observation). Whether the dimer is of physiological importance as has been demonstrated for GLUT1 [30] or just a gel artifact of solubilizing a 12-helical membrane protein in detergent is unknown. The same molecular bands were observed when purified PfHT was run on a gel and then stained with Blue Bandit protein stain (Fig 7A). To test the functional activity of PfHT in liposomes, we measured zero-trans specific uptake of \[^3H\]-D-glucose and nonspecific \[^3H\]-L-glucose (Fig 7C). Uptake was saturable with the incorporation of D-glucose ~4-fold higher than that of L-glucose indicating successful incorporation of functional PfHT protein into liposomes.

Next, we used an ATB-BMPA photolabel binding assay [24, 31] to analyze ligand binding and competition with WU-1 in PfHT-containing liposomes. Biotinylated ATB-BMPA contains the glucose analogue bis-mannose and a photolabel that can irreversibly bind to the glucose binding site of class I transporters [32]. Binding of the biotinylated photolabel to PfHT, monitored by immunoblot analysis using a fluorescently labeled streptavidin, was ~60% less in the presence of 10 \(\mu\)M WU-1 (Fig 8A), demonstrating that WU-1 binds directly to PfHT.

PfHT liposomes were then used to test the potency of WU-1 to inhibit PfHT-mediated glucose uptake. WU-1 inhibited zero-trans specific uptake (D-glucose minus L-glucose) with an \(IC_{50}\) of 5.9 ± 0.8 \(\mu\)M (Fig 8B). Due to the consistency of the \(IC_{50}\) in liposomes (5.9 ± 0.8 \(\mu\)M), in HEK293-PfHT cells (5.8 ± 0.6 \(\mu\)M), in freed parasites (6.1 ± 0.8 \(\mu\)M), coupled with the \(EC_{50}\) for growth inhibition in \(P. falciparum\) (5.5 ± 0.6 \(\mu\)M), we conclude that WU-1 kills the parasite by directly inhibiting PfHT.

**Insertion of an N-terminal FLAG tag to PfHT affects the ability of endofacial and exofacial ligands to inhibit glucose transport**

As described above, a FLAG tag was attached to the amino terminus of PfHT in order to purify PfHT prior to its reconstitution into liposomes. To test whether the FLAG tag itself affected...
PfHT transporter activity, we measured the ability of WU-1 to inhibit radiolabeled 2-DG uptake in PfHT and FLAG-tag-PfHT (FTPfHT) overexpressing cells. The WU-1 IC\textsubscript{50} value for FTPfHT was significantly right shifted compared to that for wild-type PfHT (19.5 ± 0.5 μM vs. 5.8 ± 0.6 μM, p < 0.01) indicating that WU-1 is less potent in inhibiting FLAG-tagged PfHT protein (Fig 9A). Similar results were found in liposomes, where the WU-1 IC\textsubscript{50} value for FTPfHT was 13.2 ± 3.1 μM compared to 5.9 ± 0.8 μM for PfHT (S3 Fig). Although WU-1 is a non-competitive inhibitor of PfHT in terms of zero-trans influx (Fig 6), it remains possible that WU-1 is a competitive inhibitor for zero-trans efflux as has been shown for cytochalasin B (CB) [33] and for the HIV protease inhibitor indinavir [31]. Similar to all GLUTs that are inhibited by CB, residues Q282, W388, N411, and W412 (GLUT1 nomenclature) are found in PfHT [34]. When the endofacial ligand CB was used to inhibit glucose uptake in both cell lines, like WU-1, we found that CB was significantly less potent (right-shifted) in inhibiting FTPHT than PfHT (IC\textsubscript{50} = 29.9 ± 1.8 μM vs 10.9 ± 0.9 μM, p < 0.05, Fig 9B). Using the exofacial ligand 4,6-O-ethylidene-\alpha-D-glucose, the opposite effect was observed. Ethylideneglucose was significantly more potent (left-shifted) in inhibiting FTPHT-mediated glucose uptake compared to PfHT (IC\textsubscript{50} = 1.5 ± 0.2 mM vs. 5.9 ± 0.15 mM, p < 0.001, Fig 9C). Kinetic analysis revealed that the K\textsubscript{m} for FTPHT (2.1 ± 0.5 mM) was not statistically different for that of PfHT (1.8 ± 0.3 mM) indicating that the transporter affinity for glucose was unaffected by the FLAG tag (Fig 9D). The K\textsubscript{m} for PfHT is similar to that reported for PfHT in oocytes [35].

**Discussion**

In this study, we have identified WU-1 as a small molecule inhibitor of the *P. falciparum* hexose transporter, PfHT. After improving the throughput of our previously reported 96-well cell-based assay for the screening of small molecules that inhibit glucose uptake by PfHT [15] to run in a 384-well format, we screened of the Maybridge HitFinder library of 14,399 drug-like
compounds. WU-1 exhibited potency for PfHT inhibition in the low micromolar range, efficacy in inhibiting parasite growth and excellent selectivity against the human GLUT isoforms vs. the other confirmed hits identified in the screen. The strong correlation between the IC₅₀ of WU-1 for PfHT-overexpressing HEK293 cells, EC₅₀ for parasite growth inhibition and inhibition of glucose uptake in freed parasites suggests that PfHT inhibition is the mechanism of parasite death. That WU-1 is selective for PfHT over the human orthologues is important when considering potential safety issues in non-selectively inhibiting human GLUT transporters. GLUT1 is ubiquitously expressed in most tissues and is the key GLUT for glucose transport in the brain [36]. GLUT4 is the key glucose transporter in muscle and fat for the transport of glucose in response to insulin, the inhibition of which leads to insulin resistance [37]. Thus, maintaining selectivity for PfHT over the class I GLUTs including GLUTs 1 and 4 is essential for development of an effective and safe therapeutic. Importantly, WU-1 had excellent selectivity for PfHT over insulin-dependent GLUT4 (GLUT4 IC₅₀ > 100 μM). Although the functional significance of the class II and III GLUTs has been only partially elucidated, there is high potential that disruption of the functional activity of these transporters in humans would have significant metabolic effects [38]. Thus, it is advantageous that WU-1 exhibits selectivity for PfHT over the class III transporter GLUT8, and has no effect on GLUT5, a class II transporter.

An important aspect of drug development is determining how the identified hit(s) are inhibiting the target of interest. For PfHT, if the drug binding site overlaps with the substrate...
binding site this should aid in preventing drug resistance. Specifically, mutations that prevent drug binding would be more likely to also disrupt transporter function. In PfHT overexpressing HEK293 cells, we determined that WU-1 is a noncompetitive inhibitor of PfHT-mediated zero-trans hexose influx. As for other facilitative transport proteins that mediate bi-directional flux across cell membranes, this is the expected pattern of inhibition for compounds that act at the endofacial side of the glucose permeation pathway. Inhibitor binding to the contralateral membrane surface from the measured transport rate would not be expected to be displaced by substrate. This phenomenon is well established for CB and other known endofacial GLUT ligands [31, 39]. Further support for WU-1 endofacial binding is that the IC50 for WU-1 and CB were both right-shifted in FLAG-tagged PfHT compared to PfHT over-expressing cells whereas the exofacial ligand ethylideneglucose was left-shifted. Crystallization of the protein with the drug bound would definitively identify the drug binding site similar to what was achieved for GLUT1, CB, and two Phe amide-derived inhibitors [40, 41]. Using a cell line that overexpresses FLAG-tagged PfHT, we purified PfHT to over 95% and determined it was functional and able to transport D-glucose. Expression and purification of functional PfHT is a vital step in crystalizing the protein. Using our novel ATB-BMPA assay, WU-1 inhibited ATB-BMPA binding to PfHT liposomes indicating that WU-1 interacts directly with the transporter. This was further supported by data demonstrating that WU-1 inhibits glucose uptake in liposomes containing purified PfHT with an IC50 of 5.9 ± 0.8 μM, consistent with the IC50s determined in PfHT cells and freed parasites, and the EC50 for growth inhibition.

All glucose transporters are thought to transport glucose by an alternating access mechanism in which a centrally located glucose binding site is alternatingly accessed from either side of the membrane through a series of conformational changes in the protein (Fig 10). The GLUTs as well as PfHT are members of the major facilitator superfamily (MFS) of transporters.
which all possess a characteristic fold consisting of two symmetrical six transmembrane bundles. Recently published crystal structures of GLUT1, GLUT3, GLUT5, and XylE [42–46] indicate that the alternation between outward- and inward-facing conformations is achieved via a rocker-switch motion and by a gated-pore mechanism involving transmembrane helices 7 and 10. Transition from the inward-facing to the outward-facing conformation is catalyzed by the transient formation of salt bridges at the endofacial side of the transporter. These salt bridges are formed either between the cytoplasmic ends of several transmembrane helices or between intracellular and transmembrane helices. Interestingly, the FLAG tag (DYKDDDDK) which contains seven charged amino acids may also be capable of forming transient salt bridges with residues within PfHT. Our zero-trans influx data indicates that adding a FLAG tag to the N-terminus of PfHT decreases the potency of an endofacial ligand, CB, increases the potency of the exofacial ligand, ethylideneglucose, but has no effect on the $K_m$. According to the recently published crystal structure of GLUT5, the cytoplasmic N-terminus is both facing and in close proximity to several regions involved in transient salt bridge formations in the outward-facing but not in the inward-facing conformation (Extended data Fig 7 of Reference [43]). Based on our experimental data and the published crystallographic data, we propose a model in which the FLAG tag, when attached to the N-terminus of PfHT, provides additional stabilization of the outward-facing conformation in the absence of substrate via transient salt bridges with residues found in PfHT. The actual tethering of the FLAG tag to the N-terminus of PfHT appears to be important to our experimental observations since the addition of excess FLAG peptide to PfHT liposomes had no effect on glucose uptake. In addition to the FLAG motif (DYKDDDDK), our engineered FLAG tag contains a TEV protease site (ENLYFQS) flanked on both sides by triple glycine linkers which may add crucial flexibility in salt bridge formations (see Materials and methods). Assuming a simple carrier model for PfHT, stabilization of the outward-facing conformation in a ligand empty transporter would occur by increasing the rate of step “g” relative to the rate of step “h” (Fig 10). Our hypothesis is also consistent with data reported for GLUT1 that was locked in the outward-facing conformation by an Y293I substitution [47]. This mutation decreased the $K_i$ for ethylideneglucose > 2-fold, increased the $K_i$ for CB >100-fold, and had little effect on the $K_m$. In contrast to our results, 2-DG uptake was greatly impaired presumably since GLUT1 was actually locked in one conformation, while FTPfHT is still active.

Our identification and initial characterization of a protein modification that appears to alter the conformational dynamics of PfHT has potential clinical relevance. Specifically, stabilization of the outward-facing conformation should increase the overall rate of the glucose transport cycle since there would be more ligand empty transporters primed to bind and transport extracellular glucose molecules (Fig 10). Although this would not be a desirable effect in efforts to treat malaria, our FLAG tag salt bridge hypothesis could apply to other mammalian GLUTs where increased activity would be of benefit. For example, augmentation of GLUT1 or GLUT4 intrinsic activity would be advantageous in patients with diabetes mellitus.

As with previously identified small molecule PfHT inhibitors, significant probing of identified chemical scaffolds via medicinal chemistry will be required to develop these newly identified hit compounds to the stage of lead optimization. The emergence of an expanding list of candidates greatly improves the likelihood of success in this endeavor. An advantage of the Maybridge HitFinder collection is the availability of a large set of "building block" analogs to facilitate this process.

In addition to significantly expanding the list of chemical scaffolds that can be used in the development of new anti-malarial drugs possessing optimal characteristics of efficacy, safety and durability against the development of resistance, the paradigm of targeting microbial hexose transport has significant potential for broader application. This includes other parasites
such as *Leishmania* [48] and other pathogenic microbes that possess structurally similar and functionally essential hexose transporters [49]. While homologous to mammalian transporters, our current study demonstrates that selective targeting of parasite transporters over human orthologues can be achieved.

## Supporting information

**S1 Fig. Transcriptional characterization of GLUT family members in hGLUT5- and hGLUT-T8-overexpressing HEK293-FLIP cells.** Copies of transcript per nanogram of cDNA for each glucose transporter SLC2A family member in: A) overexpression of hGLUT5 in HEK293-flip cells, B) overexpression of hGLUT8 in HEK293-FLIP cells in which native hGLUT1 expression was knocked down by siRNA as described in Materials and Methods. (TIF)

**S2 Fig. Functional activity of HEK293 cell lines.** Uptake of (A) radiolabeled 2-DG and (B) radiolabeled fructose in cell lines over-expressing the indicated hexose transporter. Data are shown as transport activity relative to untransfected HEK293 cells ± SEM of three determinations per cell line. The red line represents relative uptake in untransfected HEK293 cells. (TIF)

**S3 Fig. WU-1 is less potent in inhibiting FTPfHT transporter activity in reconstituted liposomes.** WU-1 inhibits the specific uptake ([3H]-D-glucose minus [3H]-L-glucose) into FTPfHT-containing liposomes. Different concentrations of WU-1 were added to the liposomes 20 min prior to the initiation of the transport reaction. Uptake (quenched after 50 sec) was normalized to the amount of FTPfHT in the liposomes. Data were fit by nonlinear regression analysis using GraphPad Prism 6.0 software to calculate the IC_{50} for WU-1. Data are expressed as mean ± SEM of three independent experiments. (TIF)

**S1 File. RAW data for PLOS ONE.** File contains minimal data set used to reach the conclusions drawn in the manuscript including the values behind the means, standard deviations and other measures reported, the values used to build graphs, and the points extracted from images for analysis. (XLSX)

## Author Contributions

**Conceptualization:** Monique R. Heitmeier, Richard C. Hresko, Paul W. Hruz.

**Data curation:** Monique R. Heitmeier, Richard C. Hresko, Rachel L. Edwards, Michael J. Prinsen.

**Formal analysis:** Monique R. Heitmeier, Richard C. Hresko, Rachel L. Edwards, Michael J. Prinsen, Ma Xenia G. Ilagan, Audrey R. Odom John, Paul W. Hruz.

**Funding acquisition:** Audrey R. Odom John, Paul W. Hruz.

**Investigation:** Monique R. Heitmeier, Richard C. Hresko, Audrey R. Odom John.

**Methodology:** Monique R. Heitmeier, Richard C. Hresko.

**Project administration:** Paul W. Hruz.

**Resources:** Ma Xenia G. Ilagan, Audrey R. Odom John, Paul W. Hruz.

**Supervision:** Ma Xenia G. Ilagan, Audrey R. Odom John, Paul W. Hruz.
Validation: Ma Xenia G. Ilagan.
Writing – original draft: Monique R. Heitmeier, Richard C. Hresko.
Writing – review & editing: Richard C. Hresko, Rachel L. Edwards, Michael J. Prinsen, Ma Xenia G. Ilagan, Audrey R. Odom John, Paul W. Hruz.

References
1. Organization WH. World Malaria Report 2018. Geneva, Switzerland; 2018. Report No.: 978 92 4 156552 3.
2. Rout S, Mahapatra RK. *Plasmodium falciparum*: multi-drug resistance. Chemical Biology & Drug Design.0(ia).
3. Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery—approaches and progress towards new medicines. Nature reviews Microbiology. 2013; 11(12):849–62. https://doi.org/10.1038/ nrmicro3138 PMID: 24214712
4. Vaughan AM, Kappe SHI. Malaria Parasite Liver Infection and Exoerythrocytic Biology. Cold Spring Harbor Perspectives in Medicine. 2017; 7(6).
5. Vaughan AM, Aly ASI, Kappe SHI. Malaria Parasite Pre-Erythrocytic Stage Infection: Gliding and Hiding, Cell Host & Microbe. 2008; 4(3):209–18.
6. Woodrow CJ, Penny JI, Krishna S. Intraerythrocytic *Plasmodium falciparum* expresses a high affinity facilitative hexose transporter. J Biol Chem. 1999; 274(11):7272–7. PMID: 10066789
7. Joet T, Fischbarg J, Louw AI, Eckstein-Ludwig U, Woodrow C, et al. Why is the *Plasmodium falciparum* hexose transporter a promising new drug target? Expert opinion on therapeutic targets. 2003; 7(5):593–602. https://doi.org/10.1517/14728222.7.5.593 PMID: 14498822
8. Slavic K, Delves MJ, Prudencio M, Talman AM, Straschil U, Derbyshire ET, et al. Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite’s life cycle. Antimicrob Agents Chemother. 2011; 55(6):2824–30. https://doi.org/10.1128/ AAC.01739-10 PMID: 21402842
9. Joet T, Eckstein-Ludwig U, Morin C, Krishna S. Validation of the hexose transporter of *Plasmodium falciparum* as a novel drug target. Proc Natl Acad Sci U S A. 2003; 100(13):7476–9. https://doi.org/10.1073/pnas.1330865100 PMID: 12792024
10. Blume M, Hliscs M, Rodriguez-Contreras D, Sanchez M, Landfear S, Lucius R, et al. A constitutive panhexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs. FASEB J. 2011; 25(4):1218–29. https://doi.org/10.1096/fj.10-173278 PMID: 21169382
11. Meireles P, Sales-Dias J, Andrade CM, Mello-Vieira J, Mancio-Silva L, Simas JP, et al. GLUT1-mediated glucose uptake plays a crucial role during Plasmodium hepatic infection. Cell Microbiol. 2017; 19 (2).
12. Ortiz D, Guiguenme WA, Johnson A, Ellya C, Anderson J, Clark J, et al. Identification of Selective Inhibitors of the *Plasmodium falciparum* Hexose Transporter PfHT by Screening Focused Libraries of Antimalarial Compounds. PLoS One. 2015; 10(4):e0123598. https://doi.org/10.1371/journal.pone.0123598 PMID: 25894322
13. Kraft TE, Armstrong C, Heitmeier MR, Odom AR, Hruz PW. The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrob Agents Chemother. 2015; 59 (10):6203–9. https://doi.org/10.1128/AAC.00899-15 PMID: 26248369
14. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000; 275(27):20251–4. https://doi.org/10.1074/jbc.C000228200 PMID: 10806189
15. Kraft TE, Heitmeier MR, Putanko M, Edwards RL, Ilagan MX, Payne MA, et al. A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters. Antimicrob Agents Chemother. 2016; 60(12):7407–14. https://doi.org/10.1128/AAC.02218-16 PMID: 27736766
16. Drew D, Boudker O. Shared Molecular Mechanisms of Membrane Transporters. Annual review of biochemistry. 2016; 85(1):543–72.
17. Augustin R, Riley J, Moley KH. GLUT8 contains a [DE]XXL[LI] sorting motif and localizes to a late endosomal/lysosomal compartment. Traffic. 2005; 6(12):1196–212. https://doi.org/10.1111/j.1600-0854.2005.00354.x PMID: 16262729
18. Liu H, Naismith JH. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC biotechnology. 2008; 8:91. https://doi.org/10.1186/1472-6750-8-91 PMID: 19055817

19. Lundholt BK, Scudder KM, Pagliaro L. A Simple Technique for Reducing Edge Effect in Cell-Based Assays. Journal of Biomolecular Screening. 2003; 8(5):566–70. https://doi.org/10.1177/10870510325465 PMID: 14567784

20. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science. 1976; 193(4254):673–5. PMID: 781840

21. Zhang B, Watts KM, Hodge D, Kemp LM, Hunstad DA, Hicks LM, et al. A second target of the antimalarial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry. 2011; 50(17):3570–7. https://doi.org/10.1021/bi200113y PMID: 21438569

22. Corbett Y, Herrera L, Gonzalez J, Cubilla L, Capson TL, Coley PD, et al. A novel DNA-based micro-fluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg. 2004; 70(2):119–24. PMID: 14993620

23. Saliba KJ, Krishna S, Kirk K. Inhibition of hexose transport and abrogation of pH homeostasis in the intraerythrocytic malaria parasite by an O-3-hexose derivative. FEBS Lett. 2004; 570(1–3):93–6. https://doi.org/10.1016/j.febslet.2004.06.032 PMID: 15251446

24. Hresko RC, Kraft TE, Tzekov A, Wildman SA, Hruz PW. Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding. J Biol Chem. 2014; 289(23):16100–13. https://doi.org/10.1074/jbc.M113.528430 PMID: 24706759

25. Reeves PJ, Kim JM, Khorana HG. Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. Proc Natl Acad Sci U S A. 2002; 99(21):13413–8. https://doi.org/10.1073/pnas.212519199 PMID: 12370422

26. Kraft TE, Hresko RC, Hruz PW. Expression, purification, and functional characterization of the insulin-responsive facilitative glucose transporter GLUT4. Protein Sci. 2015; 24(12):2008–19. https://doi.org/10.1002/pro.2812 PMID: 26402434

27. Hresko RC, Kraft TE, Quigley A, Carpenter EP, Hruz PW. Mammalian Glucose Transporter Activity Is Dependent upon Anionic and Conical Phospholipids. J Biol Chem. 2016; 291(33):17271–82. https://doi.org/10.1074/jbc.M116.730168 PMID: 27302065

28. Zhang JH, Chung TD, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 1999; 4(2):67–73. https://doi.org/10.1177/108705719900400206 PMID: 10838414

29. Ojelabi OA, Lloyd KP, Simon AH, De Zutter JK, Carruthers A. WZB117 (2-Fluoro-6-(m-hydroxybenzoyloxy) Phenyl m-Hydroxy benzoate) Inhibits GLUT1-mediated Sugar Transport by Binding Reversibly at the Exofacial Sugar Binding Site. J Biol Chem. 2016; 291(52):26762–72. https://doi.org/10.1074/jbc.M116.759197 PMID: 27836974

30. Hebert DN, Carruthers A. Glucose transporter oligomeric structure determines transporter function. Reversible redox-dependent interconversions of tetrameric and dimeric GLUT1. J Biol Chem. 1992; 267(33):23829–38. PMID: 1429721

31. Hresko RC, Hruz PW. HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS One. 2011; 6(9):e25237. https://doi.org/10.1371/journal.pone.0025237 PMID: 21966466

32. Koumanov F, Yang J, Jones AE, Hatanaka Y, Holman GD. Cell-surface biotinylation of GLUT4 using bis-mannose photolabels. Biochem J. 1998; 330(Pt 3):1209–15.

33. Baskettet DA, Widdas WF. Asymmetry of the hexose transfer system in human erythrocytes. Experiments with non-transporable inhibitors. Journal of Physiology. 1978; 278:389–401.

34. Ferreira RS, Pons J-L, Labesse G. Insights into Substrate and Inhibitor Selectivity among Human GLUT Transporters through Comparative Modeling and Molecular Docking. ACS Omega. 2019; 4(3):4748–60.

35. Woodrow CJ, Burchmore RJ, Krishna S. Hexose permeation pathways in Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A. 2000; 97(18):9931–6. https://doi.org/10.1073/pnas.170153097 PMID: 10954735

36. Gras D, Roze E, Caillat S, Meneret A, Doummar D, Billette de Villemeur T, et al. GLUT1 deficiency syndrome: an update. Rev Neurol (Paris). 2014; 170(2):91–9.

37. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002; 16(6):859–63. PMID: 11919487

38. Augustin R. The protein family of glucose transport facilitators: It’s not only about glucose after all. IUBMB Life. 2010; 62(5):315–33. https://doi.org/10.1002/iub.315 PMID: 20209635
39. Carruthers A, Helgerson AL. Inhibitions of sugar transport produced by ligands binding at opposite sides of the membrane. Evidence for simultaneous occupation of the carrier by maltose and cytochalasin B. Biochemistry. 1991; 30(16):3907–15. PMID: 2018762

40. Kapoor K, Finer-Moore JS, Pedersen BP, Caboni L, Waight A, Hillig RC, et al. Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides. Proc Natl Acad Sci U S A. 2016; 113(17):4711–6. https://doi.org/10.1073/pnas.1603735113 PMID: 27078104

41. Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Muller T, et al. Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876. ChemMedChem. 2016; 11(20):2261–71. https://doi.org/10.1002/cmdc.201600276 PMID: 27552707

42. Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, et al. Crystal structure of the human glucose transporter GLUT1. Nature. 2014; 510(7503):121–5. https://doi.org/10.1038/nature13306 PMID: 24847886

43. Nomura N, Verdon G, Kang HJ, Shimamura T, Nomura Y, Sonoda Y, et al. Structure and mechanism of the mammalian fructose transporter GLUT5. Nature. 2015; 526(7573):397–401. https://doi.org/10.1038/nature14909 PMID: 26416735

44. Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, et al. Crystal structure of a bacterial homologue of glucose transporters GLUT1-4. Nature. 2012; 490(7420):361–6. https://doi.org/10.1038/nature11524 PMID: 23075985

45. Deng D, Sun P, Yan C, Ke M, Jiang X, Xiong L, et al. Molecular basis of ligand recognition and transport by glucose transporters. Nature. 2015; 526(7573):391–6. https://doi.org/10.1038/nature14655 PMID: 26176916

46. Quistgaard EM, Low C, Moberg P, Tresaugues L, Nordlund P. Structural basis for substrate transport in the GLUT-homology family of monosaccharide transporters. Nat Struct Mol Biol. 2013; 20(6):766–8. https://doi.org/10.1038/nsmb.2569 PMID: 23624861

47. Mori H, Hashirmoto M, Clark AE, Yang J, Muraoka A, Tamori Y, et al. Substitution of Tyrosine-293 of Glut1 Locks the Transporter into an Outward Facing Conformation. J Biol Chem. 1994; 269(15):11578–83. PMID: 8157690

48. Feng X, Tran KD, Sanchez MA, Al Mezewghi H, Landfear SM. Glucose Transporters and Virulence in Leishmania mexicana. mSphere. 2018; 3(4):e00349–18. https://doi.org/10.1128/mSphere.00349-18 PMID: 30068561

49. Haanstra JR, Gerding A, Dolga AM, Sorgdrager FJH, Buist-Homan M, du Toit F, et al. Targeting pathogen metabolism without collateral damage to the host. Scientific Reports. 2017; 7:40406. https://doi.org/10.1038/srep40406 PMID: 28084422

50. van Schalkwyk DA, Priebe W, Saliba KJ. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J Pharmacol Exp Ther. 2008; 327(2):511–7. https://doi.org/10.1124/jpet.108.141929 PMID: 18713952